Effect of blood sugar circadian variation using the CGM of SGLT2 inhibitors in patients with type 2 diabetes

Effect of blood sugar circadian variation using the CGM of SGLT2 inhibitors in patients with type 2 diabetes - Effect of blood sugar circadian variation of SGLT2 inhibitors in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019429

Enrollment

Registered

2015-10-20

Start date

2015-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Interventions

SGLT2 inhibitors CGM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c 7.5% over Type 2 diabetes

Exclusion criteria

Exclusion criteria: Type 1 diabetes

Design outcomes

Primary

Measure	Time frame
blood sugar circadian variation	—

Countries

Japan

Contacts

Public Contactmihoko matsumura

Dokkyo Medical University Endocrinology and Metabolism

mimihoko@dokkyomed.ac.jp0282-87-2150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026